A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.
Chettab K, Fitzsimmons C, Novikov A, Denis M, Phelip C, Mathé D, Choffour PA, Beaumel S, Fourmaux E, Norca P, Kryza D, Evesque A, Jordheim LP, Perrial E, Matera EL, Caroff M, Kerzerho J, Dumontet C.
Chettab K, et al. Among authors: caroff m.
Front Immunol. 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402. eCollection 2023.
Front Immunol. 2023.
PMID: 37223101
Free PMC article.